Cargando…

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients for trastuzumab therapy. Amplification of the gene analysed by fluorescence in situ hybridisation (FISH) or overexpression of the protein determined by immunohistochemistr...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnould, L, Denoux, Y, MacGrogan, G, Penault-Llorca, F, Fiche, M, Treilleux, I, Mathieu, M C, Vincent-Salomon, A, Vilain, M O, Couturier, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377115/
https://www.ncbi.nlm.nih.gov/pubmed/12771927
http://dx.doi.org/10.1038/sj.bjc.6600943
_version_ 1782154780982902784
author Arnould, L
Denoux, Y
MacGrogan, G
Penault-Llorca, F
Fiche, M
Treilleux, I
Mathieu, M C
Vincent-Salomon, A
Vilain, M O
Couturier, J
author_facet Arnould, L
Denoux, Y
MacGrogan, G
Penault-Llorca, F
Fiche, M
Treilleux, I
Mathieu, M C
Vincent-Salomon, A
Vilain, M O
Couturier, J
author_sort Arnould, L
collection PubMed
description Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients for trastuzumab therapy. Amplification of the gene analysed by fluorescence in situ hybridisation (FISH) or overexpression of the protein determined by immunohistochemistry (IHC) are the two major methods to establish this status. A strong correlation has been previously demonstrated between these two methods. However, FISH is not always feasible in routine practice and weakly positive IHC tumours (2+) do not always correspond to a gene amplification. Our study was performed in order to evaluate the contribution of chromogenic in situ hybridisation (CISH), which enables detection of the gene copies through an immunoperoxidase reaction. CISH was performed in 79 breast carcinomas for which the HER2 status was previously determined by IHC and FISH. The results of IHC, FISH and CISH were compared for each tumour. CISH procedures were successful in 95% of our cases. Whatever the IHC results, we found a very good concordance (96%) between CISH and FISH. Our study confirms that CISH may be an alternative to FISH for the determination of the gene amplification status in 2+ tumours. Our results allow us to think that, in many laboratories, CISH may also be an excellent method to calibrate the IHC procedures or, as a quality control test, to check regularly that the IHC signal is in agreement with the gene status.
format Text
id pubmed-2377115
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23771152009-09-10 Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer Arnould, L Denoux, Y MacGrogan, G Penault-Llorca, F Fiche, M Treilleux, I Mathieu, M C Vincent-Salomon, A Vilain, M O Couturier, J Br J Cancer Genetics and Genomics Determination of the HER2/neu (HER2) status in breast carcinoma has become necessary for the selection of breast cancer patients for trastuzumab therapy. Amplification of the gene analysed by fluorescence in situ hybridisation (FISH) or overexpression of the protein determined by immunohistochemistry (IHC) are the two major methods to establish this status. A strong correlation has been previously demonstrated between these two methods. However, FISH is not always feasible in routine practice and weakly positive IHC tumours (2+) do not always correspond to a gene amplification. Our study was performed in order to evaluate the contribution of chromogenic in situ hybridisation (CISH), which enables detection of the gene copies through an immunoperoxidase reaction. CISH was performed in 79 breast carcinomas for which the HER2 status was previously determined by IHC and FISH. The results of IHC, FISH and CISH were compared for each tumour. CISH procedures were successful in 95% of our cases. Whatever the IHC results, we found a very good concordance (96%) between CISH and FISH. Our study confirms that CISH may be an alternative to FISH for the determination of the gene amplification status in 2+ tumours. Our results allow us to think that, in many laboratories, CISH may also be an excellent method to calibrate the IHC procedures or, as a quality control test, to check regularly that the IHC signal is in agreement with the gene status. Nature Publishing Group 2003-05-19 2003-05-13 /pmc/articles/PMC2377115/ /pubmed/12771927 http://dx.doi.org/10.1038/sj.bjc.6600943 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Genetics and Genomics
Arnould, L
Denoux, Y
MacGrogan, G
Penault-Llorca, F
Fiche, M
Treilleux, I
Mathieu, M C
Vincent-Salomon, A
Vilain, M O
Couturier, J
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
title Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
title_full Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
title_fullStr Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
title_full_unstemmed Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
title_short Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
title_sort agreement between chromogenic in situ hybridisation (cish) and fish in the determination of her2 status in breast cancer
topic Genetics and Genomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377115/
https://www.ncbi.nlm.nih.gov/pubmed/12771927
http://dx.doi.org/10.1038/sj.bjc.6600943
work_keys_str_mv AT arnouldl agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT denouxy agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT macgrogang agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT penaultllorcaf agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT fichem agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT treilleuxi agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT mathieumc agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT vincentsalomona agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT vilainmo agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer
AT couturierj agreementbetweenchromogenicinsituhybridisationcishandfishinthedeterminationofher2statusinbreastcancer